粘液性乳腺癌的临床研究进展

doi:10.11904/j.issn.1002-3070.2020.04.016

摘要/Abstract

摘要： 粘液性乳腺癌(Mucinous breast carcinoma,MBC)是一种来自乳房的侵袭性肿瘤。其不是乳腺癌的常见类型,关于乳腺粘液性乳腺癌的文献比较少见。基于肿瘤的细胞构成,粘液性乳腺癌分为两种亚型:单纯型乳腺粘液癌(Pure mucinous breast carcinoma,PMBC)和混合型乳腺粘液癌(Mixed mucinous breast carcinoma,MMBC)。本文将对粘液性乳腺癌的临床特征、免疫表型、基因组学、鉴别诊断、治疗和预后做一综述。

关键词: 粘液性乳腺癌, 临床特征, 免疫表型, 鉴别诊断, 治疗

Abstract: Mucinous breast cancer(MBC)is an aggressive tumor from the breast.It is not a common type of breast cancer,and the literature about mucinous breast cancer is relatively rare.Based on the cellular composition of the tumor,mucinous breast cancer is divided into two subtypes: pure type mucinous cancer(PMBC)and mixed type mucinous breast cancer(MMBC).This article reviews the clinical characteristics,immunophenotype,genomics,differential diagnosis,treatment,and prognosis of mucinous breast cancer.

Key words: Mucinous breast cancer, Clinical characteristics, Immunophenotype, Differential diagnosis, Treatment

中图分类号:

R737.9

张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.

ZHANG Rui, LI Zhigao. Clinical research progress of mucinous breast cancer[J]. Journal of Practical Oncology, 2020, 34(4): 377-381.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.04.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I4/377

参考文献

1 Di S,Gutierrez J,Avisar E.A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma[J].Breast Cancer Res Treat,2008,111(3):541-547.
2 Bae SY,Choi MY,Cho DH,et al.Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma:clinicopathologic characteristics and prognosis[J].Breast Cancer,2011,14(4):308-313.
3 Komaki K,Sakamoto G,Sugano H,et al.Mucinous carcinoma of the breast in Japan:a prognostic analysis based on morphologic features[J].Cancer,1988,61(5):989-996.
4 Cao AY,He M,Liu ZB,et al.Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma:a population-based study from China[J].Ann Surg Oncol,2012,19(9):3019-3027.
5 刘强,姚海东,林娇卡.乳腺黏液腺癌X线摄影表现与病理对照分析[J].医学影像学杂志,2014,24(2):218-221.
6 Naqos N,Naim A,Jouhadi H,et al.Mucinous carcinoma of the breast:clinical,biological and evolutive profile[J].Cancer Radiother,2016,20(8):801-804.
7 Zhang H,Qiu L,Peng Y.The sonographic findings of micropapillary pattern in pure mucinous carcinoma of the breast[J].World J Surg Oncol,2018,16(1):151.
8 Qu N,Luo Y,Yu T,et al.Differentiation between pure mucinous breast carcinomas and fibroadenomas with strong high-signal intensity on T2-weighted images from dynamic contrast-enhanced magnetic resonance imaging[J].Breast Care(Basel),2018,13(1):32-37.
9 Conant EF,Dillon RL,Palazzo J,et al.Imaging findings in mucin-containing carcinomas of the breast:correlation with pathologic features[J].AJR Am J Roentgenol,2013,163(4):821-824.
10 Chaudhry AR,Khoury M,Gotra A,et al.Imaging features of pure and mixed forms of mucinous breast carcinoma with histopathological correlation[J].Br J Radiol,2019,92(1095):810.
11 Barkley CR,Ligibel JA,Wong JS,et al.Mucinous breast carcinoma:a large contemporary series[J].Am J Surg,2008,196(4):549-551.
12 Harrison BT,Dillon DA.An update of mucinous lesions of the breast[J].Surg Pathol Clin,2018,11(1):61-90.
13 Patel S,Bhanu S,Mehta N,et al.Invasive colloid carcinoma and the role of ki67 and her2-two case reports[J].Radiol Case Rep,2018,14(3):337-342.
14 Garcia H,Canavati M,Garza M,et al.Her-2 positive mucinous carcinoma breast cancer,case report[J].Int J Surg Case Rep,2018,42(12):242-246.
15 De A,Derchain SF,Pavanello M,et al.Expression of unusual immunohistochemical markers in mucinous breast carcinoma[J].Acta Histochem,2017,119(3):327-336.
16 Rosen LE,Gattuso P.Neuroendocrine tumors of the breast[J].Arch Pathol Lab Med,2017,141(11):1577-1581.
17 Garcia L,Garza R,Barboza O,et al.Cdx-2,muc-2 and b-catenin as intestinal markers in pure mucinous carcinoma of the breast[J].Biol Res,2014,47(1):43.
18 Pareja F,Lee JY,Brown DN,et al.The genomic landscape of mucinous breast cancer[J].Natl Cancer Inst,2019,111(7):216.
19 Lacroix M,Suarez PH,MacKay A,et al.Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type[J].Pathol,2010,222(3):282-298.
20 Artibani M,Sims AH,Slight J,et al.Wt1 expression in breast cancer disrupts the epithelial mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel[J].Sci Rep,2017,27(7):45255.
21 Domfeh AB,Carley AL,Striebel JM,et al.Wt1 immunoreactivity in breast carcinoma:selective expression in pure and mixed mucinous subtypes[J].Mod Pathol,2008,21(10):1217-1223.
22 Heng C,Wei T,Yingbing T,et al.Clinicopathological characteristics of breast sebaceous adenocarcinoma[J].Pol J Pathol,2018,69(3):226-233.
23 Svajdler M,Banik P,Poliakova K,et al.Sebaceous carcinoma of the breast:report of four cases and review of the literature[J].Pol J Pathol,2015,66(2):142-148.
24 Darcy C,Quinn C.Apocrine lesions of the breast:part 1 of a two-part review:benign,atypical and in situ apocrine proliferations of the breast[J].Clin Pathol,2019,72(1):1-6.
25 Guo SP,Li QL,Wang YM,et al.Clinicopathologic features of adenoid cystic carcinoma of breast[J].Zhonghua Bing Li Xue Za Zhi,2017,46(1):25-29.
26 Limite G,Di R,Esposito E,et al.Acinic cell carcinoma of the breast:review of the literature[J].Int J Surg,2014,12(1):35-39.
27 Reyes C,Nadji M.The immunophenotype of nodular variant of medullary carcinoma of the breast[J].Appl Immunohistochem Mol Morphol,2015,23(9):624-627.
28 Liu H,Tan H,Cheng Y,et al.Imaging findings in mucinous breastcarcinoma and correlating factors[J].Eur J Radiol,2011,80(3):706-712.
29 Goto W,Kashiwagi S,Takada K,et al.A case of multiple lung metastases from breast cancer successfully treated with endocrine therapy[J].Gan To Kagaku Ryoho,2018,45(13):2426-2428.
30 Jang Y,Cho EY,Cho SY.Human epidermal growth factor receptor 2-positive mucinous carcinoma with signet ring cell differentiation,which showed complete response after neoadjuvant chemotherapy[J].Breast Cancer,2019,22(2):336-340.
31 Seki H,Sakurai T,Maeda Y,et al.Efficacy and safety of palbociclib and fulvestrant in Japanese patients with er+/her2-advanced metastatic breast cancer[J].In Vivo,2019,33(6):2037-2044.
32 Dill EA,Gru AA,Atkins KA,et al.PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages:an assessment of 245 primary and 40 metastatic tumors[J].Am J Surg Pathol,2017,41(3):334-342.
33 Zhang M,Teng XD,Guo XX,et al.Clinicopathological characteristics and prognosis of mucinous breast carcinoma[J].Cancer Res Clin Oncol,2014,140(2):265-269.
34 Skotnicki P,Sas-Korczynska B,Strzepek L,et al.Pure and mixed mucinous carcinoma of the breast:a comparison of clinical outcomes and treatment results[J].Breast J,2016,22(5):529-534.

[1]	邓俊, 袁媛, 罗璇, 谭惜颜, 于恩浩, 刘科, 吴崢, 周菊梅, 朱苏雨. 化放疗模式下早期弥漫大B细胞淋巴瘤缩小放疗野对生存预后的影响[J]. 实用肿瘤学杂志, 2020, 34(3): 237-243.
[2]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[3]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[4]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[5]	鲁雪梅, 李云涛, 安锦慧, 季国忠. 溶血磷脂酸在结直肠癌发生发展中的机制研究[J]. 实用肿瘤学杂志, 2020, 34(3): 276-281.
[6]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[7]	苏文佳, 王树叶. 滤泡性淋巴瘤的预后分层和治疗进展[J]. 实用肿瘤学杂志, 2020, 34(2): 189-192.
[8]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[9]	张景岚, 刘瑞宝. 结直肠癌肝转移瘤局部介入治疗应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 79-82.
[10]	左志博, 郭志琴, 王振, 杨宏杰, 邬万新. Semaphorin 3F在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 88-92.
[11]	曹舒, 李莎莎, 杨丹. 信号通路相关的microRNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 544-548.
[12]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[13]	张玉海, 李月敏. 人工智能在肿瘤放射治疗中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 570-574.
[14]	沈依哲, 郭宝良. 初诊Ⅳ期乳腺癌的局部治疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 575-578.
[15]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.